In addition, Jiang and colleagues reported that in vitro cytotoxicity assays were found to predict clinical efficacy of blinatumomab (an anti-CD19-targeting TCE in a BiTE format) in ALL patients [12] by introducing attenuated T cell cytotoxicity (one-third of in vitro value) while taking into account immunosuppressive environment in bone marrow in ALL patients compared with in vitro setting. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.